WorldOsteoporosisDay October 20

Gap 1: Secondary fracture prevention	2
Gap 2: Osteoporosis induced by medicines	7
Gap 3: Diseases associated with osteoporosis	11
Gap 4: Primary fracture prevention for individuals at high risk of fracture	15
Gap 5: The importance of staying on treatment	18
Gap 6: Public awareness of osteoporosis and fracture risk	20
Gap 7: Public awareness of benefits versus risks of osteoporosis treatment	22
Gap 8: Access and reimbursement for osteoporosis assessment and treatment	24
Gap 9: Prioritization of fragility fracture prevention in national policy	26
Gap 10: The burden of osteoporosis in the developing world	28



"Closing the care gap to prevent the next fracture: The UK experience."

MK Javaid

Associate Professor in Metabolic Bone Disease, University of Oxford Hon Consultant Rheumatologist, Nuffield Orthopaedic Centre

Declarations

In last five years received honoraria, travel and/or subsistence expenses from:

 Amgen, Eli Lilly, Medtronic, Norvartis, Proctor and Gamble, Servier, Shire, Internis, Consilient Health, Stirling Anglia Pharmaceuticals, Mereo Biopharma, Optasia

Clinical lead for RCP FLS database audit

Aims

UK care gap

FLS challenges

Quality improvement

More than 80% of patients after a seeing a doctor with a fragility fracture receive inadequate care.


Falling standards, broken promises

Report of the national audit of falls and bone health in older people 2010

Incident prescriptions of all anti resorptives before and after hip fracture



Prescriptions 0-4 months post



What are the barriers?

Prioritization for UK health care system-

Reduce Premature Mortality in young

Prevent Avoidable Morbidity in elderly

In 35 years:
30% increase in >65yr
100% increase in >85yr

Overwhelm health systems

Divert investment away from younger

> URGENT need to address and prevent avoidable fractures

Benefits of treatment = Current risk & drug effect


Risk of treatment harm and inconvenience




A post menopausal woman who has already had a fracture after the age of 45....


Is your risk higher compared with women of the same age without a fracture?

Low awareness of osteoporosis and fragility fracture in the UK












UK Incident Use of Alendronate



Isn't effectiveness obvious?







Regional Evaluation of Fracture Reduction Services after hip Fracture (REFRESH)

Andrew Judge

M Kassim Javaid, Cyrus Cooper, Nigel Arden, Dani Prieto-Alhambra, Andrew Farmer, Janet Lippett, Rachael Gooberman-Hill, Jose Leal, Jasroop Chana, Alastair Gray, Michael Goldacre, Laura Graham, Sam Hawley, Sally Sheard, Sarah Drew


Hospital coding: Primary hip fractures at 11 hospitals

What was the effect of FLS on re-fracture rates?

Hospital	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	Total
1	255	252	298	304	341	367	344	321	347	286	3,115
2	413	380	376	374	431	375	403	386	422	384	3,944
3	178	185	183	90	199	241	205	217	179	181	1,858
4	133	165	248	330	300	341	335	327	327	313	2,819
5	198	172	165	158	171	183	189	190	209	202	1,837
6	62	69	80	94	109	22	125	105	131	233	1,030
7	583	580	543	583	662	550	584	601	622	587	5,895
8	488	473	487	472	527	529	504	464	510	483	4,937
9	189	201	194	204	158	209	211	210	202	216	1,994
10	400	412	427	435	412	400	416	404	476	436	4,218
11	142	152	135	134	173	151	160	176	154	129	1,506
Total	3,041	3,041	3,136	3,178	3,483	3,368	3,476	3,401	3,579	3,450	33,153

Findings: second fracture within 2-years before and after FLS implementation

Forest plot of Hazard Ratios for 2-year secondary hip fracture, by type of change in service delivery



Unable to detect a change in hip re-fracture rates after introduction of an FLS with over 33,000 hip fractures

Observational study:
Before/ after time series design

Hip fractures – "too late"

Qualitative study—
"Adherence is a major issue"

No FLS delivered monitoring

Services pre-dated FLS standards




IOF standards

Aim:

- Set the standard for FLS
- 2. Guidance
- 3. Benchmarking and fine-tuning


5 domains, 13 standards


- Hip fracture patients
- Inpatient
- Outpatient
- Vertebral fracture patient
- Organization





Local decisions for an FLS > €€ vs. €€€€€€€





Key Steps in UK

Political Prioritization

Get Funded

Started

Improve and sustainable


Political Prioritization

Everyone had same message











Older people

Step 2

Political Prioritization

Get Funded

Started

Improve and sustainable

Who benefits vs. who pays?

Benefit

- Community care / Social care
- Patients and family

Costs

- Specific department in hospital
- Lower emergency admissions / income
- Regional health board


The saving: 5 year Oxford model

Population of 620,000


	Hip	Other inpatient	Outpatient	Vertebral	Total
Annual cases	622	695	2,414	555	4286
Proportion seen by FLS	95%	95%	85%	10%	
Number of fractures prevented after 5 years of FLS	288	152	152	97	629
Hospital savings at 5 years	£2.928,960	£172,064	£52,960	£314,862	£3,469,846
+ primary care/ social care/ community costs	£4,737,024	£210,064	£53,960	£336,784	£5,337,832

The cost: How big should the FLS be? Fewer Care Home admissions Dedicated Fracture Liaison Service Healthcare savings (FLS) Fewer Secondary care admissions **Identify** at risk patients Lower re-fracture Systematic investigation and risk assessment Ongoing treatment Appropriate and fracture Treatment initiation monitoring Primary care


Identification is key



24 hours pre-hip fracture network




48 hours pre-discharge: having a fracture is a full time job



Minimally disruptive Intervention


48 hours pre-discharge: having a fracture is a full time job




Minimally disruptive Intervention

FLS: Minimally disruptive Intervention






PILOT – can it work in your hospital



Monitoring


Most important step

Adherence matters: UK CPRD



• 66,116 PMO women

Prescriptions post hip fracture: UK CPRD N= 13,069



	Intervention Control			ol		Risk Ratio	Risk Ratio		
Study or Subgroup	Events Total		Events Total		Weight	M-H, Random, 95% CI	M-H, Random, 95% CI		
2.1.1 Biomarker Feed	lback								
Clowes 2004 marker	5	24	4	12	2.7%	0.63 [0.20, 1.91]			
Delmas 2007	238	1189	256	1113	41.6%	0.87 [0.74, 1.02]			
Subtotal (95% CI)		1213		1125	44.3%	0.86 [0.74, 1.01]	•		
Total events	243		260						
Heterogeneity: Tau ² =	0.00; Chi ² :	= 0.33, 0	df = 1 (P =	= 0.57)	$I^2 = 0\%$				
Test for overall effect:	Z = 1.84 (P	r = 0.07							
2.1.2 Motivational									
Clowes 2004 nurse	3	25	4	12	2.0%	0.36 [0.10, 1.36]			
Cooper 2006	235	541	315	513	47.3%	0.71 [0.63, 0.80]	=		
Schousboe 2005	13	37	9	31	6.4%	1.21 [0.60, 2.45]			
Subtotal (95% CI)		603		556	55.7%	0.76 [0.50, 1.15]			
Total events	251		328						
Heterogeneity: Tau ² =	0.06; Chi ² :	= 3.21, 0	df = 2 (P =	= 0.20)	; I ² = 38%				
Test for overall effect:	Z = 1.31 (P	= 0.19)							
Total (95% CI)		1816		1681	100.0%	0.78 [0.65, 0.95]	•		
Total events	494		588						
Heterogeneity: Tau ² =	0.02; Chi ² :	= 7.52, 0	df = 4 (P =	= 0.11)	$I^2 = 47\%$		02 05 1 2		
Test for overall effect:			-	,		E-	0.2 0.5 1 2 avours experimental Favours control		
	`	,				F	avours experimental ravours control		

Statistical but minimal clinical effect on adherence

Poor adherence: then what?

- Non-adherence is no worse than other diseases.
- Minimal impact motivation
- Switch to intermittent parenteral therapy?

Zoledronate Denosumab




Fig. 1 Persistence with and adherence to denosumab at 12 months. Data are shown as percentage ±95 % confidence interval. Persistence was defined as receiving the subsequent injection within 6 months+8 weeks of the previous injection. Adherence was defined as receiving two consecutive injections within 6 months ±4 weeks of each other

UK Key performance indicators

- Meaningful
- Measurable
- Fracture rates
- Re-fracture rates
- Time to first monitoring visit
- Number and % on anti-osteoporosis medication at 4 and 12 months
- Starting exercise within 4 months

.....from date fracture diagnosed in NHS




Helpline 0808 800 0035

Search



Donata now structions for use: element or improve Step Two w maximum flexibil rmation/data may Fracture Liaison Service Implementation Toolkit - Improvement Project Plan Tasks Commissioning organisation [Enter here] Provider organisation [Enter here] [Enter here] Project name Date [Enter here] Complete Phase Task Sub task Ref-Comments/notes Date complete by 🐷 [add new sub-task here] Process map care pathway Process map the patient journey Describe current service including areas for 2. Define and scope improvement Scope the current service Circulate document for consultation Amend documents following stakeholder comment [add new sub-task here] Identify information needed to understand current demand Identify information needed to understand future Identify information needs Identify information needed to understand costs of service [add new sub-task here] [add new task here] Request information identified in phase 2 Understand need / Identify skilled support to carry out analysis Carry out analysis of need / demand demand for service [add new sub-task here] Measure and Request information identified in phase 2 understand Estimate capacity Identify skilled support to carry out analysis required Carry out analysis of capacity required [add new sub-task here] [add new task here] Finalise care pathway Finalise service model

Oxford stakeholder map



Step 3

Political Prioritization

Get Funded

Started

Improve and sustainable


staged implementation

Set up core service

Widen case mix

Collect outcomes

Staged implementation



0 – seeing patients

- 1. Job banding, hours, start/end date
- 2. Vacancy control forms
- Adverts & Short listed
- 4. Interview panel
- 5. Notice
- 6. Contracts
- 7. Occupational health
- 8. Induction / FPP
- 9. Mandatory training
- 10. Apprenticeships

The longer you take to start the shorter the time to demonstrate outcomes

6 month project manager Work with Local Patient group

Make sure your team are trained



Fracture Prevention Practitioner certification

Introduction

Module 1 (Foundation) - Epidemiology of Ost

- Section 1 Definition
- Section 2 Incidence
- Section 3 Risk Factors

Foundation and Advanced

- Launch @ NOS 2014
- Web based podcast and assessment

Module 2 (Foundation) – Fracture Risk Assessment

- Section 1 Fracture Risk Assessment Tools
- Section 2 Nutritional Assessments
- Section 3 Bone Density Scanning (DXA)
- Section 4 Impact of Osteoporosis on the Body



Aims

Political Prioritization

Get Funded

Started

Improve and sustainable



Royal College of Physicians Fracture Liaison Service Database (FLS-DB)

FLS should perform

FLS does perform

Process

FLS-DB Facilities audit

The FLS-DB audit – patient centred



Fracture Liaison Service Database (FLS-DB) facilities audit

FLS breakpoint: opportunities for improving patient care following a fragility fracture













Key recommendations

Service providers and commissioners (or local health boards (LHBs)) should use the data in this report to review local performance and inform quality improvement. This will require collaboration and these data should form a basis for discussion to inform and improve services.

For commissioners and LHBs


- Commissioning clinical commissioning groups (CCGs) and LHBs should ensure that an effective FLS is part of its care pathway for secondary prevention of all fragility fracture groups.
- Caseload CCGs and LHBs should ensure that FLSs are commissioned to identify and treat all fracture groups such as hip fracture inpatients, other (non-hip) fracture inpatients, outpatient-treated fracture patients and vertebral fractures.

For existing FLS providers

Services should review their current service to identify any gaps and variations in secondary fracture prevention and then take the necessary steps to address these issues.

- Identification FLSs should ensure that there is a process to identify all patients aged 50 years and over with a new fragility fracture, including hip fracture patients and those with newly reported vertebral fractures.
- Bone health FLSs should ensure that all fragility fracture patients are assessed and receive treatment for bone health in line with NICE guidance. 4,5,6
- Falls assessments FLSs should link with local falls prevention services to ensure that falls assessments are performed in line with NICE guidance, and ensure rapid access to strength and balance classes that deliver the evidence-based 50 hours of supervised exercise. 7,8
- Information FLSs should ensure that core items (such as risk factors for bone health and falls and fracture risk score) are included in communications within different parts of the NHS, including primary care, and with patients.
- Monitoring FLSs should ensure that there are clear local arrangements for monitoring patients who are recommended drug therapy; these should occur within 4 months of the fracture to check successful uptake, and every 12 months to check and encourage adherence to the treatment plan. Pathways for monitoring should be agreed and responsibility for ongoing review should be specified and audited.


Reported number of patients identified by FLS (n=52) vs estimated fragility fracture caseload



Most FLSs did not see as many patients as expected:

- 24% FLS >80% estimated caseload
- 57% LFS < 50% caseload


Service structure: FLS nurse time and Estimated fragility fractures



Estimated Fragility Fractures per year

Investigation: Standard panel?

	England FLS n	England FLS %		England non FLS	Wales FLS n	Wales FLS %	Wales non FLS n	Wales non FLS		
Renal function tests	41	85.4	19	73.1	4	100.0	1	25.0		
Serum Calcium	40	83.3	18	69.2	4	100.0	1	25.0		
Liver function tests	38	79.2	18	69.2	4	100.0	1	25.0		
Full blood count	37	77.1	19	73.1	2	50.0	1	25.0		
Serum alkaline phosphate	37	77.1	17	65.4	4	100.0	1	25.0		
Serum phosphate	37	77.1	15	57.7	4	100.0	1	25.0		
Thyroid function	37	77.1	16	61.5	4	100.0	1	25.0		
Serum 250H vitamin D	36	75.0	16	61.5	3	75.0	1	25.0		
Erythrocyte sedimentation rate / ESR Liver function	29	60.4	9	34.6	1	25.0	1	25.0		
Coeliac disease screen	28	58.3	6	23.1	3	75.0	1	25.0		
Serum Electrophoresis for myeloma screen	27	56.3	15	57.7	4	100.0	1	25.0		
Serum Parathyroid hormone	26	54.2	12	46.2	3	75.0	1	25.0		
Testosterone/ Sex hormone binding globulin	24	50.0	9	34.6	4	100.0	1	25.0	England (n=48)	\\/\alos (n= 4)
C-reactive protein	20	41.7	11	Test					England (n=48)	Wales (n= 4)
Other	16	33.3	6	Rena	l func	tion to	ests		41 (85.4%)	4 (100%)
Missing	6	12.5	6	+ Ser	um Ca	alcium	1		40 (83.3%)	4 (100%)
24 hour urinary calcium	3	6.3	2	+ Serum Calcium					, ,	,
Spot urinary calcium	3	6.3	1	+ Serum phosphate					37 (77.1%)	4 (100%)
				+ Ser	um al	kaline	phos	phate	36 (75.0%)	4 (100%)
				+ Liv	er fun	ction	tests		36 (75.0%)	4 (100%)








Chart data is indicative status only - © Royal College of Physicians - Technology by Crown Informatics (ID: Main)

About this chart | How to used this chart

Records entered by Index Fragility Fracture(s) - Date diagnosed (data item 1.12)

	2016 Total = 1773												
Jan	Feb	Mar	Apr	May	June	July	Aug	Sept	Oct	Nov	Dec		
220	189	227	219	249	189	203	189	88	0	0	0		
Last Updated: 1	ast Updated: 17/10/2016 17:41												

Report for Oxfordshire Fracture Prevention Service




Chart data is indicative status only - © Royal College of Physicians - Technology by Crown Informatics (ID: Main)

out this chart | How to used this chart

Records entered by Index Fragility Fracture(s) - Date diagnosed (data item 1.12) -

	2016 Total = 1773												
Jan	Feb	Mar	Apr	May	June	July	Aug	Sept	Oct	Nov	Dec		
220	189	227	219	249	189	203	189	88	0	0	0		
ast Updated: 1	st Updated: 17/10/2016 17:41												




Chart data is indicative status only - © Royal College of Physicians - Technology by Crown Informatics (ID: Main)

About this chart | How to used this chart

Records entered by Index Fragility Fracture(s) - Date diagnosed (data item 1.12)

					2016 To	tal = 1773					
Jan	Feb	Mar	Apr	May	June	July	Aug	Sept	Oct	Nov	Dec
220	189	227	219	249	189	203	189	88	0	0	0
Last Undated: 1	7/10/2016 17:4	41									



A work in progress....

Management: more than osteoporosis medication

- Paracetamol
- Tramadol
- (NSAIDS)
- Opioid patches (3 days)
- Bowel care
- Physiotherapy
- Interventional radiology


Translation to patient care

13% of vertebral fractures are not reported by radiologists¹

35% of reports are noted by clinicians and alter patient care²

Vertebral fractures are the single most preventable fracture with current therapies $(60 - 90\%)^3$

Oxford audit



Strategy

Training

Audit

Staged introduction

Feedback





ABOUT US

WHAT WE DO

OSTEOPOROSIS & MUSCULOSKELETAL DISORDERS & ATAD PUBLICATIONS GET INVOLVED


MEETINGS & EVENTS

NEWS & MULTIMEDIA

↑ ↑ ★ WOMEN OVER 50 WILL EXPERIENCE OSTEOPOROTIC FRACTURES. AS WILL # # # MEN

Home - What We Do - Training and Education - Educational Slide Kits -

VERTEBRAL FRACTURE TEACHING PROGRAM






Reprints

IOF publications and resources are available for reprint. Click here for further information and to download permission form


Faculty/Acknowledgement


VFI Resource Document Lead Authors Judy Adams Neil Binkley



ICSD 2015

- Lateral Spine imaging with Standard Radiography or Densitometric VFA is indicated when T-score is
 - < -1.0 and one or more of the following is present:
 - Women age ≥ 70 years or men
 ≥ age 80 years
 - Historical height loss > 4 cm (>1.5 inches)
 - Self-reported but undocumented prior vertebral fracture
 - Glucocorticoid therapy equivalent to ≥ 5 mg of prednisone or equivalent per day for ≥ 3 months





Choose your words wisely


End plate depression


Vertebral deformity

Biconcave/ wedge deformity

Vertebral body height loss

vertebral body collapse






Falls

- Anti-osteoporosis Medication take >6 months to reduce fracture
- Falls interventions
 - Timely
 - Adhered to

- Strength and Balance exercise program
- Medication review
- Eye sight
- Home Occupational therapy review



Help is at hand



ABOUT BEST PRACTICE FRAMEWORK GET MAPPED

RESOURCES

CONTACT

Online Ouestionnaire

Map of best practice

Mentorship Programme

MENTORSHIP PROGRA

View

Edit

Manage display

IOF has developed a mentorship programme to enable FLS implementation worldwide. To achieve this goal, IOF was and skills by connecting experienced FLS champions with any institutions willing to establish a new FLS.

THE MENTORSHIP PROGRAMME INCLUDES TWO ASPECTS:

ON-SITE TRAINING DAY.

This activity allows an FLS candidate (mentee) to benefit from a "one-day visit" at the FLS champion's institution (mentor). Material and certificate will be provided. IOF will cover the travel cost for the FLS candidate.

A limited number of on-site training days will be available each year.

If you want to establish an FLS and would like to apply for the on-site training day, please contact Muriel Schneider for more information.

2. CTF FLS WORKSHOP

2 workshops this year: Russia &

This workshop aims to teach the basic steps on FLS implementation to a group of 15-20 FLS candidates (mentees) within the same country. In close collaboration with a national society, the CTF FLS workshop will be customized to the health system of the country by including local experts within the speaker panel. Course Materials and certificates of attendance will be provided to the mentees.

A limited number of workshops will be available each year.

If you are a national society and/or a well-established FLS and would like to organize a CTF FLS workshop in your country, please contact Muriel Schneider at capturethefracture@iofbonehealth.org for more information.


5 site visits

sponsored


each year

Czech Republic

Aims of Mentoring: Achieving the FLS escalator



1. Describe the patient pathway



Regional network

Fracture Reduction in South Central PolicY group



A network of every bone clinician/ Nurse (11 Basingstoke Basingstoke Southampton Southampton

AIM:

Every patient with a fragility fracture over the age of 50yr in South Central is:

- Identified
- Assessed
- 3. Treated effectively for at least five years for both bone and falls health

Fracture Liaison Service > Fracture Prevention Service

Portsmouth

What is the regional gap: 2009

2009 Case mix of patients receiving secondary fracture prevention

	Site	Inpatients		Outpatient	Vertebral fractures	
		Hip fracture Nonhip fracture				
Berkshire	Reading					
	Wexham					
Bucks	Milton Keynes					
	Stoke Mandeville					
Oxfordshire	John Radcliffe					
	Horton					

Green – systematic coverage

Orange – partial/ in development

Red – no coverage

What is the regional gap: 2015

2015 Case mix of patients receiving secondary fracture prevention

	Site	Inpatients		Outpatient	Vertebral fractures
		Hip fracture			
Berkshire	Reading				
	Wexham				
Bucks	Milton Keynes				
	Stoke Mandeville				
Oxfordshire	John Radcliffe				
	Horton				

Green – systematic coverage

Orange – partial/ in development

Red – no coverage

Developed shared guidance



Who to assess

Secondary Screen

DXA indications

Atypical fractures

Vitamin D therapy

Treatment thresholds

Tailored treatment initiation

Treatment duration

Switching after adverse events

Monitoring Questions

Monitoring frequency

Switching after re-fracture

Renal disease

Developed shared guidance

Danube- Adria
Osteoporosis Society

Who to assess

Secondary Screen

DXA indications

Atypical fractures

Vitamin D therapy

Treatment thresholds

Tailored treatment initiation

Treatment duration

Switching after adverse events

Monitoring Questions

Monitoring frequency

Switching after re-fracture

Renal disease

SUMMARY

- UK Focus on secondary fracture prevention
 - Multiple stakeholders > unified goal with patients
 - Population approach not hospital based
 - Start small and build up
 - Use the CTF (toolkit, implementation team, events)



National Institute for Health Research



Oxford Team past and present:

Cooper, Arden, Wass, Willett, Carr, Price, Glyn-Jones, Hamdy, Ramasay A Soni, K Leyland, S Sheard, R Warne, D Prieto Alhambra, A Judge, S Hawley, R Pinedo-Villanueva, G Round, R Batra, A Kiran, D Hunter



RUDY team

A Turner

J Barrett

J Hogg

R Popert

D Grey

N Grey

H Teare

J Kaye

R Lugmani

P Wordsworth

MSK RD-TRC RUDY / GeCIP team

MSK RD-TRC RUDY / GeCIP team

Rajesh Thakker <rajesh.thakker@ndm.ox.ac.uk>, Shine Brian (RTH) OUH <Brian.Shine@ouh.nhs.uk>, Faisal Ahmed <Faisal. Fadii Hannan <a href="faith-Daniel Perry <danperry@doctors.org.uk>

Osaka

K Kato

M Kokado

IOF CtF CSA

K Akesson

P Mitchell

M Edwards

S Goemaere

T Thomas

WF Lems

D O'Gradaigh

M Schneider

Dominique Pierroz

C Cooper



